Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2011-12-26

Clinical Trial Update: Low Dose Decitabine + Interferon Alfa-2b in Advanced Renal Cell Carcinoma [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating low-dose decitabine plus interferon alfa-2b in advanced renal cell carcinoma was terminated, with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Dacogen (decitabine)
  • Intron A (interferon alfa-2b)

Snippet

Sponsor: M.D. Anderson Cancer Center | Conditions: Renal Cell Carcinoma | Phase 2 | Status: TERMINATED | Results posted: 2011-12-26